No abstract available
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects
-
Apoptosis Regulatory Proteins / genetics*
-
Apoptosis Regulatory Proteins / physiology
-
Bcl-2-Like Protein 11
-
Benzamides
-
Chromosome Banding
-
Drug Administration Schedule
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Humans
-
Imatinib Mesylate
-
Introns / genetics*
-
Japan
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Membrane Proteins / genetics*
-
Membrane Proteins / physiology
-
Molecular Targeted Therapy
-
Patient Selection
-
Piperazines / administration & dosage
-
Piperazines / pharmacology
-
Piperazines / therapeutic use*
-
Polymorphism, Genetic*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins / physiology
-
Pyrimidines / administration & dosage
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use*
-
Recurrence
-
Remission Induction
-
Sequence Deletion*
-
Time Factors
Substances
-
Antineoplastic Agents
-
Apoptosis Regulatory Proteins
-
BCL2L11 protein, human
-
Bcl-2-Like Protein 11
-
Benzamides
-
Membrane Proteins
-
Piperazines
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
Pyrimidines
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl